MannKind Corp
MNKD4.950USD
-0.089-1.79%
Handelsschluss 05/01, 16:00（ET）Kurse um 15 Minuten verzögert
1.50BMarktkapitalisierung
54.36KGV TTM
mehr Informationen über MannKind Corp Unternehmen
MannKind Corporation is focused on the development and commercialization of inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. The Company's technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices. In its endocrine business unit, it commercializes two products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Its pipeline products include Pediatric Afrezza (insulin human) Inhalation Powder, MNKD-101 and MNKD-201.
Unternehmensinformationen
Unternehmens-codeMNKD
Name des UnternehmensMannKind Corp
IPO-datumJul 28, 2004
Gegründet am1991
CEODr. Michael E. Castagna, Pharm.D.
Anzahl der mitarbeiter407
WertpapierartOrdinary Share
GeschäftsjahresendeJul 28
Addresse1 Casper Street
StadtDANBURY
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl06810
Telefon18186615000
Websitehttps://mannkindcorp.com/
Unternehmens-codeMNKD
IPO-datumJul 28, 2004
Gegründet am1991
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Michael E. Castagna, Pharm.D.
Dr. Michael E. Castagna, Pharm.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.47M
-2.62%
Mr. Steven B. Binder
Mr. Steven B. Binder
Director
Director
696.53K
-9.51%
Dr. David B. Thomson, J.D., Ph.D.
Dr. David B. Thomson, J.D., Ph.D.
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
609.34K
+16.18%
Mr. Dominic (Nick) Marasco
Mr. Dominic (Nick) Marasco
President, Endocrine Business Unit
President, Endocrine Business Unit
252.00K
--
Dr. Burkhard Blank, M.D.
Dr. Burkhard Blank, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
194.25K
-28.25%
Mr. Anthony C. (Tony) Hooper
Mr. Anthony C. (Tony) Hooper
Independent Director
Independent Director
176.15K
--
Mr. Ronald J. Consiglio
Mr. Ronald J. Consiglio
Independent Director
Independent Director
118.43K
--
Ms. Jennifer Grancio
Ms. Jennifer Grancio
Independent Director
Independent Director
110.70K
--
Dr. Sabrina Kay
Dr. Sabrina Kay
Independent Director
Independent Director
107.03K
--
Ms. Lauren M. Sabella
Ms. Lauren M. Sabella
Executive Vice President - Operations
Executive Vice President - Operations
106.41K
-45.01%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Michael E. Castagna, Pharm.D.
Dr. Michael E. Castagna, Pharm.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.47M
-2.62%
Mr. Steven B. Binder
Mr. Steven B. Binder
Director
Director
696.53K
-9.51%
Dr. David B. Thomson, J.D., Ph.D.
Dr. David B. Thomson, J.D., Ph.D.
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
609.34K
+16.18%
Mr. Dominic (Nick) Marasco
Mr. Dominic (Nick) Marasco
President, Endocrine Business Unit
President, Endocrine Business Unit
252.00K
--
Dr. Burkhard Blank, M.D.
Dr. Burkhard Blank, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
194.25K
-28.25%
Mr. Anthony C. (Tony) Hooper
Mr. Anthony C. (Tony) Hooper
Independent Director
Independent Director
176.15K
--
Umsatzaufteilung
Währung: USDUpdate-Zeit: Sun, Apr 6
Währung: USDUpdate-Zeit: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Product sales
178.56M
62.54%
Royalties
102.33M
35.84%
Services
4.61M
1.62%
Nach RegionUSD
Name
Umsatz
Anteil
United States
285.50M
0.00%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Product sales
178.56M
62.54%
Royalties
102.33M
35.84%
Services
4.61M
1.62%
Aktionäre
Update-Zeit: Sun, Feb 23
Update-Zeit: Sun, Feb 23
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
6.98%
The Vanguard Group, Inc.
5.26%
State Street Global Advisors (US)
3.27%
Avoro Capital Advisors LLC
2.88%
Nitorum Capital, L.P.
2.88%
Other
78.72%
Aktionärsstatistik
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
6.98%
The Vanguard Group, Inc.
5.26%
State Street Global Advisors (US)
3.27%
Avoro Capital Advisors LLC
2.88%
Nitorum Capital, L.P.
2.88%
Other
78.72%
Art
Aktionäre
Anteil
Investment Advisor/Hedge Fund
24.45%
Investment Advisor
16.58%
Hedge Fund
10.78%
Research Firm
3.38%
Individual Investor
1.63%
Pension Fund
0.35%
Bank and Trust
0.33%
Venture Capital
0.02%
Other
42.48%
Institutionelle Beteiligung
Update-Zeit: Tue, Mar 4
Update-Zeit: Tue, Mar 4
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
464
175.74M
57.84%
+7.73M
2024Q4
470
175.08M
57.68%
+5.91M
2024Q3
459
161.03M
58.24%
+6.62M
2024Q2
442
145.29M
52.88%
-4.76M
2024Q1
433
140.98M
52.03%
-8.31M
2023Q4
422
141.98M
52.59%
-12.51M
2023Q3
418
148.17M
55.00%
-3.06M
2023Q2
412
143.59M
53.56%
-12.28M
2023Q1
412
147.80M
55.93%
-4.58M
2022Q4
408
144.92M
55.01%
+311.67K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
21.21M
6.98%
+360.93K
+1.73%
Dec 31, 2024
The Vanguard Group, Inc.
16.00M
5.26%
+420.33K
+2.70%
Dec 31, 2024
State Street Global Advisors (US)
9.95M
3.27%
+350.64K
+3.65%
Dec 31, 2024
Avoro Capital Advisors LLC
8.75M
2.88%
--
--
Dec 31, 2024
Nitorum Capital, L.P.
8.75M
2.88%
-410.19K
-4.48%
Dec 31, 2024
Geode Capital Management, L.L.C.
6.37M
2.1%
+35.35K
+0.56%
Dec 31, 2024
Two Sigma Investments, LP
6.27M
2.06%
+579.24K
+10.18%
Dec 31, 2024
Arrowstreet Capital, Limited Partnership
4.89M
1.61%
+3.59M
+275.93%
Dec 31, 2024
Fidelity Management & Research Company LLC
4.48M
1.47%
+49.96K
+1.13%
Dec 31, 2024
D. E. Shaw & Co., L.P.
4.27M
1.41%
+798.47K
+23.01%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: Sun, Apr 6
Update-Zeit: Sun, Apr 6
Name
Anteil
Invesco Biotechnology & Genome ETF
2.16%
ALPS Medical Breakthroughs ETF
1.21%
VictoryShares Small Cap Free Cash Flow ETF
0.61%
Federated Hermes MDT Small Cap Core ETF
0.54%
First Trust Small Cap Growth AlphaDEX Fund
0.41%
Invesco NASDAQ Future Gen 200 ETF
0.4%
Global X Aging Population ETF
0.32%
iShares Micro-Cap ETF
0.29%
SPDR S&P Biotech ETF
0.28%
First Trust Small Cap Core Alphadex Fund
0.22%
Mehr Anzeigen
Invesco Biotechnology & Genome ETF
Anteil2.16%
ALPS Medical Breakthroughs ETF
Anteil1.21%
VictoryShares Small Cap Free Cash Flow ETF
Anteil0.61%
Federated Hermes MDT Small Cap Core ETF
Anteil0.54%
First Trust Small Cap Growth AlphaDEX Fund
Anteil0.41%
Invesco NASDAQ Future Gen 200 ETF
Anteil0.4%
Global X Aging Population ETF
Anteil0.32%
iShares Micro-Cap ETF
Anteil0.29%
SPDR S&P Biotech ETF
Anteil0.28%
First Trust Small Cap Core Alphadex Fund
Anteil0.22%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten